158 related articles for article (PubMed ID: 18806695)
1. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
[TBL] [Abstract][Full Text] [Related]
2. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
[TBL] [Abstract][Full Text] [Related]
3. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
[TBL] [Abstract][Full Text] [Related]
5. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
7. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Dickinson L; Boffito M; Back D; Waters L; Else L; Davies G; Khoo S; Pozniak A; Aarons L
J Antimicrob Chemother; 2009 Jun; 63(6):1233-43. PubMed ID: 19329800
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Panhard X; Legrand M; Taburet AM; Diquet B; Goujard C; Mentré F;
Eur J Clin Pharmacol; 2007 Nov; 63(11):1019-29. PubMed ID: 17694300
[TBL] [Abstract][Full Text] [Related]
15. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
16. Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
Cattaneo D; Meraviglia P; Cozzi V; Baldelli S; Milani G; Clementi E
Fundam Clin Pharmacol; 2012 Apr; 26(2):204-6. PubMed ID: 21210843
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV
Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
[TBL] [Abstract][Full Text] [Related]
19. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
[TBL] [Abstract][Full Text] [Related]
20. Atazanavir: new option for treatment of HIV infection.
Havlir DV; O'Marro SD
Clin Infect Dis; 2004 Jun; 38(11):1599-604. PubMed ID: 15156449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
